Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Summit Therapeutics Inc.

NASDAQ: SMMT · Life Sciences · 7 alerts · CIK 1599298

Share price
$11.82Close, Nov 16
Market cap
$9.45B
Shares outstanding
799.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Summit Therapeutics Inc. filings on SEC EDGAR ↗

5:08 PM ET 10-Q
Financial Results

Summit Therapeutics Q3 2026 Results: Net Loss of $208M, Loss Narrows

Summit Therapeutics reported a net loss of $613.5 million for the nine months ended September 30, 2026, compared to a net loss of $860.4 million in the prior year period. The company ended the quarter with $629.8 million in cash, cash equivalents, and short-term investments, while total stockholders' equity decreased to $564.7 million from $658.9 million at year-end 2025.

Key figure
Net loss $208M
4:52 PM ET 8-K
Financial Results

Summit Therapeutics Financial Results

Summit Therapeutics reported its Q3 2026 financial results, highlighting a $2.0 billion strategic equity investment from AstraZeneca received post-quarter. The company ended the period with $629.8 million in cash and is advancing its global clinical development program for ivonescimab across multiple solid tumor indications.

“This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others.”

Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit

“Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC- 20 platform study.”

Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.